SynthesisFrontiers in oncology2021

Current Evidence of the Efficacy and Safety of Neoadjuvant EGFR-TKIs for Patients With Non-small Cell Lung Cancer.

Xiaoshun Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.